-
Achilles Therapeutics NasdaqCM:ACHL Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Location: 245 Hammersmith Road, London, W6 8PW, United Kingdom | Website: https://www.achillestx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
0.00
Cash
159.3M
Avg Qtr Burn
N/A
Short % of Float
2.29%
Insider Ownership
6.29%
Institutional Own.
83.10%
Qtr Updated
03/31/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ATL001 (cNeT) +/- Nivolumab (anti-PD-1) Details Melanoma, Cancer, Solid tumor/s | Failed Discontinued | |
ATL001 (TIL cNeT) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Failed Discontinued |